How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,528 results for

Fibrosis Probability Score

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Fibrosis Probability Score

Fibrosis Probability Score Fibrosis Probability Score Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Fibrosis Probability Score (...) Fibrosis Probability Score Aka: Fibrosis Probability Score , FIB-4 Index II. Indications risk for fibrosis assessment for Fibrosis ( ) III. Criteria Score = (Age x AST) / ( x sqrRoot(ALT)) IV. Interpretation Score <1.45: Negative for Score >3.25: Consistent with V. Efficacy : 85% : 65% VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Fibrosis Probability Score." Click on the image (or right click) to open the source

2018 FP Notebook

2. Fibrosis Probability Score

Fibrosis Probability Score Fibrosis Probability Score Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Fibrosis Probability Score (...) Fibrosis Probability Score Aka: Fibrosis Probability Score , FIB-4 Index II. Indications risk for fibrosis assessment for Fibrosis ( ) III. Criteria Score = (Age x AST) / ( x sqrRoot(ALT)) IV. Interpretation Score <1.45: Negative for Score >3.25: Consistent with V. Efficacy : 85% : 65% VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Fibrosis Probability Score." Click on the image (or right click) to open the source

2017 FP Notebook

3. Impact of preoperative biopsy on severe submucosal fibrosis on endoscopic submucosal dissection for colorectal laterally spreading tumors: a propensity score analysis. (PubMed)

the effect of biopsy sampling on submucosal fibrosis and treatment outcomes of ESD for laterally spreading tumors (LSTs).Between April 2005 and September 2015, 441 consecutive patients underwent colorectal ESD in Osaka City University Hospital. Using propensity score matching and inverse probability of treatment weighting (IPTW), we retrospectively evaluated risk factors for severe submucosal fibrosis and treatment outcomes for patients with LSTs, with or without preoperative biopsy sampling.A total (...) Impact of preoperative biopsy on severe submucosal fibrosis on endoscopic submucosal dissection for colorectal laterally spreading tumors: a propensity score analysis. It is believed that preoperative biopsy sampling for superficial-type colorectal tumors should be avoided because submucosal fibrosis caused by biopsy sampling makes EMR impossible. However, few studies have reported the influence of biopsy sampling on colorectal endoscopic submucosal dissection (ESD). This study aimed to examine

2018 Gastrointestinal endoscopy

4. Symptom Score to Assess Abdominal Involvement in Patients With Cystic Fibrosis

Symptom Score to Assess Abdominal Involvement in Patients With Cystic Fibrosis Symptom Score to Assess Abdominal Involvement in Patients With Cystic Fibrosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Symptom Score to Assess Abdominal Involvement in Patients With Cystic Fibrosis (CF Abd-Score) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03052283 Recruitment Status : Recruiting First Posted : February 14, 2017 Last

2017 Clinical Trials

5. Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V

at outcome level 26 2.5.2 Overall conclusion on added benefit 27 2.6 List of included studies 28 References for English extract 29 Extract of dossier assessment A18-08 Version 1.0 Lumacaftor/ivacaftor (cystic fibrosis) 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iv - List of tables 2 Page Table 2: Research question of the benefit assessment of lumacaftor/ivacaftor 1 Table 3: Lumacaftor/ivacaftor – probability and extent of added benefit 6 Table 4: Research question (...) : lumacaftor/ivacaftor + BST vs. placebo + BST 26 Table 17: Positive and negative effects from the assessment of lumacaftor/ivacaftor + BST in comparison with placebo + BST 27 Table 18: Lumacaftor/ivacaftor – probability and extent of added benefit 27 2 Table numbers start with “2” as numbering follows that of the full dossier assessment. Extract of dossier assessment A18-08 Version 1.0 Lumacaftor/ivacaftor (cystic fibrosis) 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - v

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08

: Lumacaftor/ivacaftor – probability and extent of added benefit 7 Addendum A18-39 Version 1.0 Lumacaftor/ivacaftor – Addendum to Commission A18-08 10 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy CF cystic fibrosis CFQ-R Cystic Fibrosis Questionnaire Revised CFTR cystic fibrosis transmembrane conductance regulator CSR clinical study report FEV1 forced expiratory volume in 1 second G-BA Gemeinsamer (...) Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08 1 Translation of addendum A18-39 Lumacaftor/Ivacaftor (zystische Fibrose) – Addendum zum Auftrag A18-08 (Version 1.0; Status: 10 July 2018). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 10 July 2018 1.0 Commission: A18-39 Version: Status: IQWiG Reports – Commission No. A18-39

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. (PubMed)

A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. Midwall myocardial fibrosis on cardiovascular magnetic resonance (CMR) is a marker of early ventricular decompensation and adverse outcomes in aortic stenosis (AS). We aimed to develop and validate a novel clinical score using variables associated with midwall fibrosis.One hundred forty-seven patients (peak aortic velocity (Vmax) 3.9 [3.2,4.4] m/s) underwent CMR to determine midwall fibrosis (CMR cohort (...) ). Routine clinical variables that demonstrated significant association with midwall fibrosis were included in a multivariate logistic score. We validated the prognostic value of the score in two separate outcome cohorts of asymptomatic patients (internal: n = 127, follow-up 10.3 [5.7,11.2] years; external: n = 289, follow-up 2.6 [1.6,4.5] years). Primary outcome was a composite of AS-related events (cardiovascular death, heart failure, and new angina, dyspnoea, or syncope). The final score consisted

Full Text available with Trip Pro

2016 European Heart Journal

8. What is the most accurate and cost-effective direct test (ELF test, hyaluronic acid, P3NP, Fibroscan or ARFI elastography) for detecting and staging liver fibrosis and/or cirrhosis in patients with diagnosed or suspected non-alcoholic fatty liver disease,

, the analysis was conducted over a lifetime horizon and both costs and QALYs were discounted at an annual rate of 3.5%. Transition probabilities between health states in the model were derived from UK data. 9.1. Hepatitis B HBeAg-positive and HBeAg-negative patients with hepatitis B and suspected fibrosis or cirrhosis who would normally have a liver biopsy to assess eligibility for antiviral treatment were included in this analysis. A METAVIR score of F=2 equated to a positive test result and treatment (...) than the indirect APRI and FIB4 scores for detection of significant fibrosis. Fibroscan® had higher sensitivity than the indirect APRI and FIB4 scores for detection of fibrosis and cirrhosis. ? No studies were identified that compared serum biomarkers with ARFI elastography, P3NP with any other non-invasive liver fibrosis test, or serum biomarkers with each other. ? In HBeAg-positive patients, testing with hyaluronic acid resulted in 11.66 QALYs gained per patient at a total cost of £79,084

2018 Evidence Notes from Healthcare Improvement Scotland

9. A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis (PubMed)

A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis Midwall myocardial fibrosis on cardiovascular magnetic resonance (CMR) is a marker of early ventricular decompensation and adverse outcomes in aortic stenosis (AS). We aimed to develop and validate a novel clinical score using variables associated with midwall fibrosis.One hundred forty-seven patients (peak aortic velocity (Vmax) 3.9 [3.2,4.4] m/s) underwent CMR to determine midwall fibrosis (CMR cohort (...) ). Routine clinical variables that demonstrated significant association with midwall fibrosis were included in a multivariate logistic score. We validated the prognostic value of the score in two separate outcome cohorts of asymptomatic patients (internal: n = 127, follow-up 10.3 [5.7,11.2] years; external: n = 289, follow-up 2.6 [1.6,4.5] years). Primary outcome was a composite of AS-related events (cardiovascular death, heart failure, and new angina, dyspnoea, or syncope). The final score consisted

Full Text available with Trip Pro

2015 EvidenceUpdates

10. Diagnosis of Idiopathic Pulmonary Fibrosis

Diagnosis of Idiopathic Pulmonary Fibrosis AMERICANTHORACICSOCIETY DOCUMENTS DiagnosisofIdiopathic PulmonaryFibrosis An Of?cial ATS/ERS/JRS/ALAT Clinical Practice Guideline Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal (...) recommend serological testing to exclude connective tissue disease (CTD) as a potential cause of the ILD (motherhood statement). For patients with newly detected ILD of apparently unknown cause who are clinically suspected of having IPF and have an HRCT pattern of probable UIP, indeterminate for UIP, or an alternative diagnosis: d We suggest cellular analysis of their BAL ?uid (conditional recommendation, very low quality of evidence). d We suggest surgical lung biopsy (SLB) (conditional recommendation

2018 American Thoracic Society

11. Modulator Treatments for Cystic Fibrosis: Effectiveness and Value

of children aged 6 to 11 years with R117H residual function mutations, those on Kalydeco experienced statistically significant worsening of lung function and trended towards decreased respiratory symptom-related quality of life scores compared to placebo. ©Institute for Clinical and Economic Review, 2018 Page ES5 Evidence Report – Cystic Fibrosis Return to Table of Contents Four randomized controlled trials (RCTs) – STRIVE, ENVISION, KONNECTION, and KONDUCT – evaluated the safety and efficacy of Kalydeco (...) (-0.08, 0.20) BMI z-score: 0.04 (-0.15, 0.07) 5.1 (3.2, 7.0) Symdeko vs. Orkambi Network Meta-Analysis Indirect comparison EVOLVE vs. Tr/Tr 1.2 (-0.1, 2.5) 0.87 (0.53, 1.42) 2.9 (0.0, 5.8) EVOLVE vs. Ratjen BMI z-score: -0.04 (-0.29, 0.21) Results in bold font are statistically significant. Abbreviations: BMI: body mass index, CFQ-R: Cystic Fibrosis Questionnaire-Revised, Diff: difference between Kalydeco and placebo, nd: no data (not reported), ppFEV1: predicted percent forced expiratory volume

2018 California Technology Assessment Forum

12. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis

fibrosis assessment method in the United States. It can be performed at bedside in an ambulatory office setting, is rapid to perform, has a wide range of scores (2.5−75 kPa), is associated with acceptable intra-observer and inter-observer reproducibility, and has been validated in large cohorts worldwide in a spectrum of liver diseases, including hepatitis B, hepatitis C, fatty liver disease, and autoimmune liver disorders, among others. By applying a probe to the intercostal skin in the 9 th to 11 th (...) intercostal space in a region 25−65 mm (M-probe) or 35−75 mm (XL-probe) below the skin surface, a minimum of 10 valid liver stiffness measurements are obtained to derive a composite score used to estimate stage of liver fibrosis, which is determined to be of adequate quality if there are at least 10 validated measurements and the interquartile range/median value of liver stiffness is ≤30%. x 18 Castera, L., Forns, X., and Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography

2017 American Gastroenterological Association Institute

13. Transient Elastography at 50Hz for the diagnosis of Liver Fibrosis in patients with confirmed Hepatitis B or confirmed Hepatitis C

fibrosis stages, transition probabilities between fibrosis stages (i.e. F1-F4), probability of hepatocellular carcinoma, treatment effectiveness, mortality of liver complications and age-related mortality, utility scores of the various liver fibrosis stages, and the costs of diagnosis and treatment. The key results are presented in Tables 2 and 3. 9 Table 2: Key results of hepatitis C economic evaluation Scenario Test Mean LY a Mean Costs Mean QALYs Inc Costs Inc QALYs ICER TE plus clinical assessments (...) , sensitivity ranged from 83% to 89% and specificity ranged from 90% to 95% for cirrhosis. When compared with liver biopsy, the accuracy of TE in identifying HBV patients with significant fibrosis requiring treatment (METAVIR score = 2), sensitivity ranged from 71% to 84% and specificity ranged from 72% to 84% for detection of significant fibrosis. In HCV, sensitivity for significant fibrosis ranged from 70% to 79% and specificity ranged from 80% to 86%. MSAC noted that, evidence comparing the diagnostic

2016 Medical Services Advisory Committee

14. Enhanced liver fibrosis test

a single score by combining, in an algorithm, the quantitative measurements of three direct serum markers including hyaluronic acid (HA), amino-terminal pro-peptide of type III pro-collagen (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1) for the detection of hepatic fibrosis. The diagnostic performance of the OELF (ELF plus age) has been compared with liver biopsy in the European Liver Fibrosis study, an international, multicentre, cross-sectional study. 1 This study demonstrated (...) viral hepatitis) who also underwent liver biopsy. 7 Using the manufacturer’s cutoffs, the sensitivity of the ELF test for identifying advanced fibrosis was 74.4 per cent and the specificity was 92.4 per cent, however it was less accurate in diagnosing significant fibrosis and cirrhosis. The ELF score was more likely to incorrectly classify patients if they were =45 years of age, and less likely to incorrectly classify patients in the presence of steatosis. The authors concluded that the test

2016 COAG Health Council - Horizon Scanning Technology Briefs

15. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. (PubMed)

The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Recent studies have suggested that non-definitive patterns on high-resolution CT (HRCT) scan provide sufficient diagnostic specificity to forgo surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis (IPF). The objective of this study was to determine test characteristics of non-definitive HRCT patterns for identifying histopathological usual interstitial pneumonia (...) had a specificity of 91.2% (95% CI 87.2% to 94.3%) and a positive predictive value (PPV) of 62.5% (95% CI 49.5% to 74.3%) for UIP pattern on surgical lung biopsy. The addition of age, sex and total traction bronchiectasis score improved the PPV. Inconsistent with UIP pattern demonstrated poor PPV (22.7%, 95% CI 18.3% to 27.7%). HRCT pattern specificity was nearly identical in the validation cohort (92.7%, 95% CI 82.4% to 98.0%). The substantially higher prevalence of UIP pattern in the validation

Full Text available with Trip Pro

2017 Thorax

16. Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis

Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02632123 Recruitment Status : Recruiting First Posted : December 16, 2015 Last Update Posted

2015 Clinical Trials

17. Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease (PubMed)

from non-liver-related diseases according to the degrees of steatosis and fibrosis using the competing risk method. We used the NAFLD fibrosis score (NFS) to assess fibrosis severity and the ultrasonography fatty liver score to evaluate steatosis severity. The numbers of patients with NFS indicating low, intermediate, and high probabilities of advanced fibrosis were 2,451 (60.2%), 1,462 (35.9%), and 160 (3.9%), respectively. Of the 4,073 patients, 179 died during follow-up, but only nine deaths (...) Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease In patients with nonalcoholic fatty liver disease (NAFLD), prognosis and outcome, especially non-liver-related mortality, remain incompletely elucidated. We clarified the mortality from all causes in patients with NAFLD. A total of 4,073 patients with NAFLD diagnosed by ultrasonography were enrolled. We investigated the causes of death and analyzed the mortality

Full Text available with Trip Pro

2017 Hepatology communications

18. Noninvasive scoring algorithm to identify significant liver fibrosis among treatment-naive chronic hepatitis C patients. (PubMed)

Noninvasive scoring algorithm to identify significant liver fibrosis among treatment-naive chronic hepatitis C patients. Staging for liver fibrosis is recommended in the management of hepatitis C as an argument for treatment priority. Our aim was to construct a noninvasive algorithm to predict the significant liver fibrosis (SLF) using common biochemical markers and compare it with some existing models.The study group included 104 consecutive cases; SLF was defined as Ishak fibrosis stage (...) greater than 2. The patient population was assigned randomly to the training and the validation groups of 52 cases each. The training group was used to construct the algorithm from parameters with the best predictive value. Each parameter was assigned a score that was added to the noninvasive fibrosis score (NFS). The accuracy of NFS in predicting SLF was tested in the validation group and compared with APRI, FIB4, and Forns models.Our algorithm used age, alkaline phosphatase, ferritin, APRI, α2

2014 European journal of gastroenterology & hepatology

19. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. (PubMed)

scores of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis.This was a non-randomised longitudinal study, including adults with T2D who were self-enrolled to the CCI (n=262) or to receive usual care (UC, n=87) during 1 year. An NAFLD liver fat score (N-LFS) >-0.640 defined the presence of fatty liver. An NAFLD fibrosis score (NFS) of >0.675 identified subjects with advanced fibrosis. Changes in N-LFS and NFS at 1 year were the main endpoints.At baseline, NAFLD was present in 95 (...) % of patients in the CCI and 90% of patients in the UC. At 1 year, weight loss of ≥5% was achieved in 79% of patients in the CCI versus 19% of patients in UC (p<0.001). N-LFS mean score was reduced in the CCI group (-1.95±0.22, p<0.001), whereas it was not changed in the UC (0.47±0.41, p=0.26) (CCI vs UC, p<0.001). NFS was reduced in the CCI group (-0.65±0.06, p<0.001) compared with UC (0.26±0.11, p=0.02) (p<0.001 between two groups). In the CCI group, the percentage of individuals with a low probability

Full Text available with Trip Pro

2019 BMJ open

20. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. (PubMed)

modified Rodnan skin score (mRSS) ≥7, valid mRSS at 12±3 months after baseline and ≥1 annual follow-up visit. Progressive skin fibrosis was defined as an increase in mRSS >5 and ≥25% from baseline to 12±3 months. Outcomes were pulmonary, cardiovascular and renal progression, and all-cause death. Associations between skin progression and outcomes were evaluated by Kaplan-Meier survival analysis and multivariable Cox regression.Of 1021 included patients, 78 (7.6%) had progressive skin fibrosis (skin (...) Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. To determine whether progressive skin fibrosis is associated with visceral organ progression and mortality during follow-up in patients with diffuse cutaneous systemic sclerosis (dcSSc).We evaluated patients from the European Scleroderma Trials and Research database with dcSSc, baseline

Full Text available with Trip Pro

2019 Annals of the rheumatic diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>